The weekly litigation news digest is live. Subscribe now

IP Verse

Hetero Labs competitive analysis

Loading summary...

Latest oppositions filed by Hetero Labs

Explore patent oppositions filed by Hetero Labs against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 20, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3133070
Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The PatientGENZYMEMay 14, 2020

Latest PTAB cases involving Hetero Labs

Discover the latest PTAB cases involving Hetero Labs, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Hetero Labs with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 20, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
HETERO LABS1 - - -
GENZYME - 1925